May 27, 2020

Pliant Therapeutics- $100 Million

South San Francisco, CA ; 3/3/20

Amount Funded: $100 Million

Type: Series C

Lead Investor: Novartis

Participating Investor(s): Redmile Group, Farallon Capital Mgmt. , Cormorant Asset Mgmt., Surveyor Captial, Logos Capital (new investors); Agent Capital, Cowen Healthcare Investments, Schroder Adveq, SCubed Capital, Menlo Ventures, undisclosed institutional investors

Company Description: Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases.

What funding will be used for: Supporting the continued clinical development of therapies for fibrotic diseases and continuing ongoing discovery programs for fibrotic diseases. 


“Our team is proud to have the support and strategic expertise provided by this group of world-class investors to help us achieve our vision of developing transformative medicines for patients living with devastating fibrotic diseases.This financing will support the continued clinical development of our lead product candidate in IPF and PSC, as well as our continued strategy to build our pipeline of proprietary product candidates for a wide range of other fibrotic diseases.”

-Bernard Coulie, M.D., Ph. D., President and CEO, Pliant Therapeutics


Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.



StartupsOne features relevant, focused news on venture capital funding of technology oriented startup businesses based in North America.

View all posts by StartupsOne →